This will take effect February 4, 2013
Overview and Clinical Utility:
Effective February 4, 2013 PathGroup will implement ImmunoCAP allergy testing on the Phadia 250. ImmunoCAP specific IgE is an in vitro quantitative assay which measures the concentration of circulating allergen specific IgE in human serum or plasma samples. It is intended for in vitro diagnostic use as an aid in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings.
Click Here to read more.